• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

    11/3/21 8:00:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGTX alert in real time by email

    PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for companies in manufacturing and technology industries.

    Lisa Ricciardi, Cognition's president and CEO, stated, "Ellen's expertise leading companies and serving shareholder interests on public company boards will be a valuable addition to our organization. Her career working in operations and financial capacities across diverse industries has afforded Ellen valuable perspectives. We look forward to leveraging her experiences as we evolve our business."

    Mrs. Richstone currently serves on the boards of eMagin, a company developing OLED microdisplay technology for virtual and augmented reality applications; Superior Industries International, a manufacturer of cast aluminum automotive wheels; and Orion Energy Systems, a company dedicated to the manufacture of sustainable and energy efficient LED lighting systems. Earlier in her career, she was chief financial officer at public and private companies ranging in size up to Fortune 500, including Sonus Networks, Rohr Aerospace (Fortune 500) and Augat (former public company, now a division of TE Connectivity Ltd), in which positions she completed and integrated over 35 acquisitions and raised a combined $1 billion in equity and debt.

    Mrs. Richstone graduated from Scripps College in Claremont, California and holds a Master of Arts in international affairs and a Master of Arts in Law and Diplomacy (MALD) with a specialty in international business law from the Fletcher School of Law and Diplomacy at Tufts University. In addition, she completed the Advanced Professional Certificate in Finance at New York University's Graduate School of Business Administration. In 2020, Mrs. Richstone was named to the National Association of Corporate Directors (NACD) Directorship 100 for her work in board leadership and governance; and in 2013, was given the Distinguished Director Award from the American College of Corporate Directors. She also sits on the board of the New England chapter of the National Association of Corporate Directors.

    About Cognition Therapeutics:

    Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of management of Cognition Therapeutics, Inc. (the "Company"). These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section of the Company's prospectus, dated October 7, 2021, that was filed with the Securities and Exchange Commission ("SEC") under File No. 333-257999 and elsewhere in filings with the SEC available at www.sec.gov, as the same may be supplemented or superseded from time to time by the Company's future periodic reports, including its Annual Reports on Form 10-K. Any forward-looking statements that the Company makes in this announcement speak only as of the date of this press release, and the Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

    Contact Information:

    Cognition Therapeutics, Inc.

    [email protected]

    Aline Sherwood (media)

    Scienta Communications

    [email protected]

    Lisa Sher (investors)

    Tiberend Strategic Advisors, Inc.

    [email protected]



    Primary Logo

    Get the next $CGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGTX

    DatePrice TargetRatingAnalyst
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    11/3/2021$27.00Buy
    B. Riley Securities
    11/3/2021$22.00Outperform
    Oppenheimer
    More analyst ratings

    $CGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cognition Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

      12/19/24 7:33:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Cognition Therapeutics from Overweight to Neutral

      7/30/24 6:19:11 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Cognition Therapeutics with a new price target

      B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00

      11/3/21 8:37:44 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

      - End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. During the meeting, the Cognition team will review results of the Phase 2 'SHINE' study (NCT03507790) of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease. In addition, proposed

      6/25/25 7:30:23 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

      Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute   PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provide

      6/3/25 7:30:02 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

      PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of retinal cells, leading to irreversible vision loss," stated Mary Hamby, PhD, vice president of research. "Preclinical research presented at ARVO supports our understanding of zervime

      5/9/25 7:30:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

      PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard

      5/1/23 7:30:44 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

      PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,

      10/11/22 8:00:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

      PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c

      11/3/21 8:00:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    SEC Filings

    See more
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/20/25 4:01:35 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/3/25 7:39:52 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

      6/2/25 6:01:27 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      2/4/25 4:11:53 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ricciardi Lisa bought $9,975 worth of shares (5,700 units at $1.75), increasing direct ownership by 2% to 291,345 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      3/14/24 4:34:10 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care